What's the optimal steroid taper for a patient with giant cell arteritis?

Question

Henry Bergman · Accepted Answer

<keypoints>
- **Induction:** Prednisolone 40–60 mg/day orally; use IV methylprednisolone 0.25–1 g/day for 3 days if ischaemic complications (visual loss, amaurosis fugax, stroke) are present, then revert to oral
- **Taper target:** Reach ≤15–20 mg/day by 2–3 months, then ≤5 mg/day by 12 months (EULAR)
- **BSR taper schedule:** Reduce by 10 mg every 2 weeks to 20 mg → 2.5 mg every 2–4 weeks to 10 mg → 1 mg every 1–2 months thereafter
- **Alternate-day dosing: avoid** — associated with higher relapse rates
- **Total duration:** Typically 1–2 years; some patients require longer
- **Tocilizumab** (IL-6 receptor inhibitor): ACR/VF conditionally recommends adding tocilizumab to steroids for newly diagnosed GCA; enables significantly shorter steroid tapers (26-week protocol) and reduces relapse risk
- **Relapse management:** Minor relapse → increase to last effective dose or 5–15 mg above current dose; major relapse → re-induct at 40–60 mg/day
- **Bone protection** should be co-prescribed in…

Phase	Action
Weeks 0–4	Maintain induction dose (40–60 mg/day)
Weeks 4–8	Reduce by 10 mg every 2 weeks → target 20 mg/day
~Month 2–6	Reduce by 2.5 mg every 2–4 weeks → target 10 mg/day
Month 6–12	Reduce by 1 mg every 4–8 weeks → target ≤5 mg/day
Year 2+	Continue slow taper toward cessation, guided by symptoms and inflammatory markers

Heidi Desktop goes where the browser can’t.

Heidi Desktop goes where the browser can’t.

What's the optimal steroid taper for a patient with giant cell arteritis?

Key Points

How is every Heidi Answer reviewed?

Induction Dose

Taper Schedule (Standard — BSR/EULAR)

Tocilizumab: Shorter Steroid Taper Option

Monitoring & Relapse

Adjunct Considerations